None

None

None

SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney. These drugs also improve body weight, blood pressure, and cardiac function. Based on these …

Effect of 1 25-dihydroxyvitamin D3 Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

The aim of this study is to assess the effects of 1,25(OH)2D3 on insulin secretion by the pancreas and glucose utilization by skeletal muscle as well as to determine the effects of 1,25(OH)2D3 on muscle strength in pre-diabetic persons

Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients

Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes or pre-diabetes. The main objective is to measure the cumulative incidence of diabetes and pre-diabetes 6 months after TIPS insertion.

Study of the Factors Favoring the Transition From Prediabetes to Diabetes on Reunion Island.

It is important in Reunion island, in view of the specificities presented by our population, to understand the pre-diabetes / diabetes transition and the risk and protective factors.

The Effect of Time-Restricted Eating in Cardiometabolic Health

The proposed studies will elucidate the cardiometabolic implications of TRE in people with obesity and prediabetes.

The Alberta NutrIMM Study - Nutrition and Immunity

Excess weight, nutrition, and blood sugar levels can all affect immune function, which in turn can affect participants risk for heart disease and type 2 diabetes (T2DM). It is not known how diet, blood sugar, and weight affect immune function. The purpose of the study is to look at how …

Complex All-comers and Patients With Diabetes or Prediabetes Treated With Xience Sierra Everolimus-eluting Stents

Clinical outcome of patients with previously unknown (silent) diabetes and prediabetes is of increasing interest since the latter group has recently shown to be associated with a significant risk of adverse cardiovascular events after treatment with contemporary DES.